Pretty exciting to watch this story unfold. I only had time to skim the blog but will read it again tonight. I got the impression mgmt. is leaning towards the IPO route since it may be the quickest path to 'monetizing' dx, thereby funding tx and getting this stock out of sub.20 land. An IPO gets the parent company cash now as well as the chance for a bigger reward later, after ambs dx has matured and lympro and ms precise have proven their value with revenue. I assume parent co. would keep most of the cash as payment for the IP and we'd keep a majority equity stake in the dx company as well. Love the prospect of ambs collecting royalties and potentially a huge payoff with sale of the dx co. to BP later.
Some questions I have that I'd like to research later ...
- How long does it typically take to set up an IPO?
- How much is ambs dx worth right now in an IPO? 100m ? more? (Long term, I'd agree its value is over 1B. But it would be a startup co. at this point).
- Will ambs dx need to hire a CEO prior to IPO?
- It's been discussed before but would the parent company be able to differentiate between "long-term" and "short-term" investors when distributing a tx share dividend? If so, how?
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links